13,742 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by EntryPoint Capital LLC

Key Points

• EntryPoint Capital LLC acquired 13,742 shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) valued at approximately $185,000 during the 1st quarter.
• Analysts have revised their target prices for VRDN, with Wells Fargo lowering it to $26.00, and The Goldman Sachs Group raising it to $30.00, while most analysts maintain a consensus rating of "Moderate Buy."
• Viridian Therapeutics reported ($1.00) earnings per share in the most recent quarter, meeting analysts' estimates, with a slight increase in revenue compared to the same quarter last year.

EntryPoint Capital LLC bought a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 13,742 shares of the company's stock, valued at approximately $185,000.

Other institutional investors also recently bought and sold shares of the company. Deep Track Capital LP increased its position in shares of Viridian Therapeutics by 20.6% in the fourth quarter. Deep Track Capital LP now owns 4,522,741 shares of the company's stock valued at $86,701,000 after buying an additional 771,796 shares in the last quarter. Tang Capital Management LLC lifted its position in shares of Viridian Therapeutics by 11.1% during the 4th quarter. Tang Capital Management LLC now owns 2,492,925 shares of the company's stock valued at $47,789,000 after buying an additional 250,000 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Viridian Therapeutics by 2,847.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,326,811 shares of the company's stock valued at $25,436,000 after buying an additional 1,281,799 shares in the last quarter. Parkman Healthcare Partners LLC lifted its position in shares of Viridian Therapeutics by 155.9% during the 4th quarter. Parkman Healthcare Partners LLC now owns 1,087,634 shares of the company's stock valued at $20,850,000 after buying an additional 662,634 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Viridian Therapeutics by 1.2% during the 1st quarter. Northern Trust Corp now owns 702,517 shares of the company's stock valued at $9,470,000 after buying an additional 8,375 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on VRDN shares. Wells Fargo & Company decreased their target price on Viridian Therapeutics from $27.00 to $26.00 and set an "equal weight" rating on the stock in a research report on Thursday, August 7th. Needham & Company LLC decreased their target price on Viridian Therapeutics from $36.00 to $34.00 and set a "buy" rating on the stock in a research report on Wednesday, August 6th. Royal Bank Of Canada decreased their target price on Viridian Therapeutics from $45.00 to $41.00 and set an "outperform" rating on the stock in a research report on Thursday, August 7th. The Goldman Sachs Group increased their target price on Viridian Therapeutics from $27.00 to $30.00 and gave the company a "buy" rating in a research report on Thursday, August 7th. Finally, Oppenheimer increased their target price on Viridian Therapeutics from $28.00 to $32.00 and gave the company an "outperform" rating in a research report on Thursday, August 7th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.00.

Viridian Therapeutics Trading Up 6.7%

Shares of VRDN stock opened at $19.23 on Monday. The stock's fifty day moving average is $16.60 and its two-hundred day moving average is $15.09. The company has a debt-to-equity ratio of 0.04, a quick ratio of 11.01 and a current ratio of 11.01. The firm has a market capitalization of $1.57 billion, a P/E ratio of -5.02 and a beta of 0.42. Viridian Therapeutics, Inc. has a fifty-two week low of $9.90 and a fifty-two week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($1.00) earnings per share for the quarter, meeting analysts' consensus estimates of ($1.00). Viridian Therapeutics had a negative return on equity of 78.95% and a negative net margin of 112,806.88%.The company had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.05 million. During the same quarter last year, the firm posted ($0.81) EPS. The firm's revenue for the quarter was up 4.2% on a year-over-year basis. Research analysts expect that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.